Novel combination treatments targeting chronic myeloid leukemia stem cells.

[1]  T. Brümmendorf,et al.  Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. , 2011, Blood.

[2]  A. Bennaceur-Griscelli,et al.  Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. , 2011, Blood.

[3]  Susan Branford,et al.  BCR–ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment , 2011, Clinical Cancer Research.

[4]  Angelo J. Canty,et al.  Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.

[5]  I. Flinn,et al.  Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. , 2011, The Lancet. Oncology.

[6]  M. Gonen,et al.  Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. , 2011, Blood.

[7]  S. Kimura,et al.  Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen , 2011, Oncogene.

[8]  C. Glorieux,et al.  Molecular chaperone Hsp90 as a target for oxidant-based anticancer therapies. , 2011, Current medicinal chemistry.

[9]  M. Baccarani,et al.  Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Varma,et al.  Role of hTERT and WT1 gene expression in disease progression and imatinib responsiveness of patients with BCR–ABL positive chronic myeloid leukemia , 2011, Leukemia & lymphoma.

[11]  C. Rudin,et al.  Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors , 2011, Clinical Cancer Research.

[12]  J. Radich,et al.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. , 2011, Blood.

[13]  W. Meng,et al.  Activation of the hedgehog pathway in chronic myelogeneous leukemia patients , 2011, Journal of experimental & clinical cancer research : CR.

[14]  Thomas Ernst,et al.  Impact of BCR-ABL mutations on patients with chronic myeloid leukemia , 2011, Cell cycle.

[15]  B. Druker,et al.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. , 2011, The Journal of clinical investigation.

[16]  M. Zahurak,et al.  Characterization of chronic myeloid leukemia stem cells , 2011, American journal of hematology.

[17]  Claude Preudhomme,et al.  Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. , 2010, The New England journal of medicine.

[18]  E. Vellenga,et al.  BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells. , 2010, Blood.

[19]  D. Proia,et al.  Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. , 2010, Blood.

[20]  T. Clackson,et al.  Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia , 2010, Clinical Cancer Research.

[21]  Martin C. Müller,et al.  Molecular Response <1% BCR-ABL IS at 12 Months Is Associated with Improved Overall and Progression-Free Survival. the Randomized German CML-Study IV , 2010 .

[22]  J. Radich,et al.  Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). , 2010, Blood.

[23]  Philippe Rousselot,et al.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.

[24]  C. Eaves,et al.  Insights into the stem cells of chronic myeloid leukemia , 2010, Leukemia.

[25]  J. Melo,et al.  Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR , 2010, Leukemia.

[26]  M. Andreeff,et al.  The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? , 2010, Seminars in hematology.

[27]  Anjana Rao,et al.  NFAT, immunity and cancer: a transcription factor comes of age , 2010, Nature Reviews Immunology.

[28]  Arunasree M. Kalle,et al.  Bcr-Abl-independent mechanism of resistance to imatinib in K562 cells: Induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs). , 2010, Leukemia research.

[29]  H. Dombret,et al.  Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 study , 2010, Cancer.

[30]  M. Baccarani,et al.  The response to imatinib and interferon-α is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase , 2010, Haematologica.

[31]  T. Phang,et al.  Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. , 2010, Cancer cell.

[32]  T. Skorski,et al.  Chronic myeloid leukemia: mechanisms of blastic transformation. , 2010, The Journal of clinical investigation.

[33]  Manuel Ayala,et al.  Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. , 2010, The New England journal of medicine.

[34]  Ricardo Pasquini,et al.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. , 2010, The New England journal of medicine.

[35]  C. Jamieson,et al.  Molecular pathways to CML stem cells , 2010, International journal of hematology.

[36]  P. Manley,et al.  Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  G. Stingl,et al.  fc24 Lde225, a specific smoothened inhibitor, for the topical treatment of nevoid basal cell carcinoma syndrome (gorlin's syndrome) , 2010 .

[38]  Lixin Lang,et al.  A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. , 2010 .

[39]  R. Larson,et al.  Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib. , 2010 .

[40]  J. Baselga,et al.  A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors. , 2010 .

[41]  Yan Wang,et al.  Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML). , 2010, Genes & cancer.

[42]  T. Holyoake,et al.  Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. , 2010, Cancer cell.

[43]  E. Reddy,et al.  A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. , 2010, Genes & cancer.

[44]  P. LoRusso,et al.  Review: Targeting the Hedgehog pathway in cancer , 2010, Therapeutic advances in medical oncology.

[45]  G. Gigli,et al.  Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells. , 2010, Nanomedicine.

[46]  Martin C. Müller,et al.  Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Yukio Kondo,et al.  TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia , 2010, Nature.

[48]  Martin C. Müller,et al.  Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib , 2010, Haematologica.

[49]  J. Radich,et al.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  C. Rudin,et al.  Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. , 2009, The New England journal of medicine.

[51]  P. Atadja,et al.  Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. , 2009, Blood.

[52]  Xiaoyan Jiang,et al.  A Novel AHI-1-BCR-ABL-JAK2 Interaction Complex Mediates Cellular Resistance to Tyrosine Kinase Inhibitors in CML . , 2009 .

[53]  J. Strovel,et al.  Inhibition of Wnt/β-Catenin Signaling by AV65 Treatment Caused Cell Cycle Arrest and Induced Caspase-Independent or -Dependent Apoptosis in CML Cells. , 2009 .

[54]  M. Konopleva,et al.  Inhibition of Bcl-2/Bcl-XL Promotes Apoptosis in Blast Crisis CML Including Quiescent Primitive Progenitor Cells Regardless of Cellular Responses to Tyrosine Kinase Inhibitors. , 2009 .

[55]  H. Kantarjian,et al.  Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study. , 2009 .

[56]  M. Copland,et al.  Combination of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib Eliminates Chronic Myeloid Leukemia Stem and Progenitor Cells. , 2009 .

[57]  J. Radich,et al.  A Phase I Study of the HDAC Inhibitor LBH589 in Combination with Imatinib for Patients with CML in Cytogenetic Remission with Residual Disease Detectable by Q-PCR. , 2009 .

[58]  M. Konopleva,et al.  Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells , 2009, Molecular Cancer Therapeutics.

[59]  R. Larson,et al.  Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  J. Radich,et al.  Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. , 2009, Blood.

[61]  T. Suda,et al.  Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon–dependent exhaustion , 2009, Nature Medicine.

[62]  C. Peng,et al.  Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia , 2009, Nature Genetics.

[63]  M. Baccarani,et al.  Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  P. Atadja,et al.  Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells , 2009, Cancer biology & therapy.

[65]  Andreas Trumpp,et al.  IFNα activates dormant haematopoietic stem cells in vivo , 2009, Nature.

[66]  Tannishtha Reya,et al.  Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia , 2009, Nature.

[67]  Yanli Jin,et al.  Triptolide Inhibits Bcr-Abl Transcription and Induces Apoptosis in STI571-resistant Chronic Myelogenous Leukemia Cells Harboring T315I Mutation , 2009, Clinical Cancer Research.

[68]  Jorge Cortes,et al.  Molecular biology of bcr-abl1-positive chronic myeloid leukemia. , 2009, Blood.

[69]  Yiguo Hu,et al.  Inhibitory Effects of Omacetaxine on Leukemic Stem Cells and BCR-ABL-Induced Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Mice , 2009, Leukemia.

[70]  R. Zini,et al.  Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. , 2008, Blood.

[71]  J. Strovel,et al.  A Novel β-catenin Inhibitor, AV65 Suppresses the Growth of CML Cell Lines Which Acquire Imatinib-Resistance Because of Abl Kinase Domain Mutations Including T315I and Hypoxia-Adaptation. , 2008 .

[72]  K. Bhalla,et al.  Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies. , 2008 .

[73]  A. Lin,et al.  AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells , 2008, The Journal of experimental medicine.

[74]  M. Pirmohamed,et al.  Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. , 2008, Blood.

[75]  R. Clark,et al.  A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials , 2008, Leukemia.

[76]  M. Warmuth,et al.  Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. , 2008, Cancer cell.

[77]  Jaspal Kaeda,et al.  Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  D. Scadden,et al.  Evolving concepts on the microenvironmental niche for hematopoietic stem cells , 2008, Current opinion in hematology.

[79]  Yasuo Ikeda,et al.  PML targeting eradicates quiescent leukaemia-initiating cells , 2008, Nature.

[80]  J. Melo,et al.  Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications , 2008, Clinical Cancer Research.

[81]  S. Oliveria,et al.  Resistance to imatinib among patients in chronic phase (CP) of chronic myelogenous leukemia (CML) in clinical practice , 2008 .

[82]  R. Means,et al.  Self-Renewal of Acute Lymphocytic Leukemia Cells Is Limited by the Hedgehog Pathway Inhibitors Cyclopamine and IPI-926 , 2008, PloS one.

[83]  T. Reya,et al.  Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In Vivo , 2007 .

[84]  A. Strasser,et al.  ABT‐737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug‐resistance mechanisms , 2007, British journal of haematology.

[85]  P. Dent,et al.  Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. , 2007, Blood.

[86]  G. Ossenkoppele,et al.  Imatinib Resistance and/or Intolerance in Clinical Practice in Europe: The “Unmet Needs in CML and Ph+ALL” (UNIC) Study. , 2007 .

[87]  T. Holyoake,et al.  Effective Induction of Apoptosis in Chronic Myeloid Leukemia CD34+ Cells by the Histone Deacetylase Inhibitor LAQ824 in Combination with Imatinib. , 2007 .

[88]  H. Kantarjian,et al.  Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure , 2007, Cancer.

[89]  G. Daley,et al.  Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single‐agent therapy with imatinib , 2007, Cancer.

[90]  C. Peng,et al.  Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. , 2007, Blood.

[91]  J. Melo,et al.  The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. , 2007, Blood.

[92]  T. Holyoake,et al.  Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. , 2007, Blood.

[93]  M. Gasparetto,et al.  Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies , 2007, Leukemia.

[94]  M. Baccarani,et al.  Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. , 2007, Blood.

[95]  Z. Zehner,et al.  TGFbeta1 regulation of vimentin gene expression during differentiation of the C2C12 skeletal myogenic cell line requires Smads, AP-1 and Sp1 family members. , 2007, Biochimica et biophysica acta.

[96]  B. Brors,et al.  Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase , 2007, Leukemia.

[97]  Z. Estrov,et al.  Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy , 2007, Cancer.

[98]  Lee L. Rubin,et al.  Targeting the Hedgehog pathway in cancer , 2006, Nature Reviews Drug Discovery.

[99]  R. A. Etten,et al.  Requirement for CD44 in homing and engraftment of BCR-ABL–expressing leukemic stem cells , 2006, Nature Medicine.

[100]  A. Strasser,et al.  Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic , 2006, Proceedings of the National Academy of Sciences.

[101]  K. Bhalla,et al.  Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate–Sensitive or Imatinib Mesylate–Resistant Chronic Myelogenous Leukemia Cells , 2006, Clinical Cancer Research.

[102]  P. Atadja,et al.  Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. , 2006, Blood.

[103]  H. Kantarjian,et al.  Janus kinase 2: a critical target in chronic myelogenous leukemia. , 2006, Cancer research.

[104]  James R. Porter,et al.  Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. , 2006, Journal of medicinal chemistry.

[105]  M. Copland,et al.  Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. , 2006, Blood.

[106]  M. Wittekind,et al.  The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. , 2006, Cancer research.

[107]  C. Marosi,et al.  In vivo effects of imatinib mesylate on human haematopoietic progenitor cells , 2006, European journal of clinical investigation.

[108]  Jie Wu,et al.  Potent Inhibition of Platelet-Derived Growth Factor-Induced Responses in Vascular Smooth Muscle Cells by BMS-354825 (Dasatinib) , 2006, Molecular Pharmacology.

[109]  P. Valent,et al.  Detection of molecular targets on the surface of CD34+/CD38− stem cells in various myeloid malignancies , 2006, Leukemia & lymphoma.

[110]  S. Kambhampati,et al.  Differential regulation of the p70 S6 kinase pathway by interferon α (IFNα) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells , 2005 .

[111]  C. Huff,et al.  Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors , 2005, British journal of haematology.

[112]  James Bradner,et al.  Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 , 2005, Journal of Biological Chemistry.

[113]  T. Holyoake,et al.  Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro , 2005, Leukemia.

[114]  J. Issa,et al.  Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  J. Mestan,et al.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.

[116]  D. Marin,et al.  Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib , 2005, Cancer.

[117]  S. Derdak,et al.  Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. , 2005, Blood.

[118]  C. Sawyers,et al.  Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. , 2005, Blood.

[119]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[120]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[121]  P. Atadja,et al.  Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo , 2004, Leukemia.

[122]  I. Weissman,et al.  JunB Deficiency Leads to a Myeloproliferative Disorder Arising from Hematopoietic Stem Cells , 2004, Cell.

[123]  Ayalew Tefferi,et al.  Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. , 2004, Blood.

[124]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[125]  Jie Jin,et al.  Triptolide Down-regulates Bcr-abl Expression and Induces Apoptosis in Chronic Myelogenous Leukemia Cells , 2004, Leukemia & lymphoma.

[126]  Susan Branford,et al.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.

[127]  M. Andreeff,et al.  Results of triple therapy with interferon‐alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in early chronic phase , 2003, Cancer.

[128]  P. Atadja,et al.  Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. , 2003, Cancer research.

[129]  F. Şahin,et al.  Involvement of protein phosphatase 2A in interferon-alpha-2b-induced apoptosis in K562 human chronic myelogenous leukaemia cells. , 2003, Leukemia research.

[130]  K. Bhalla,et al.  Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. , 2003, Blood.

[131]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[132]  Hui-Kuan Lin,et al.  Jak2 is involved in c-Myc induction by Bcr-Abl , 2002, Oncogene.

[133]  G. Daley,et al.  Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. , 2002, Blood.

[134]  J. Licht,et al.  Histone deacetylases as therapeutic targets in hematologic malignancies. , 2002, Current opinion in hematology.

[135]  M. Slovak,et al.  Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. , 2002, Blood.

[136]  S. Rane,et al.  JAKs, STATs and Src kinases in hematopoiesis , 2002, Oncogene.

[137]  Massimo Gadina,et al.  Cytokine Signaling in 2002 New Surprises in the Jak/Stat Pathway , 2002, Cell.

[138]  M. Andreeff,et al.  Simultaneous homoharringtonine and interferon‐α in the treatment of patients with chronic‐phase chronic myelogenous leukemia , 2002, Cancer.

[139]  AC Eaves,et al.  Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia , 2002, Leukemia.

[140]  Yan Wang,et al.  Involvement of Jak2 tyrosine phosphorylation in Bcr–Abl transformation , 2001, Oncogene.

[141]  Amit Verma,et al.  The p38 MAPK Pathway Mediates the Growth Inhibitory Effects of Interferon-α in BCR-ABL-expressing Cells* , 2001, The Journal of Biological Chemistry.

[142]  K. Bhalla,et al.  Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. , 2001, Cancer research.

[143]  B. Cheson,et al.  Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  L. Neckers,et al.  The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[145]  C. Eaves,et al.  Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. , 1999, Blood.

[146]  Z. Estrov,et al.  The biology of chronic myeloid leukemia. , 1999, The New England journal of medicine.

[147]  H. Nakshatri,et al.  Regulation of the c-jun Gene in p210 BCR-ABL Transformed Cells Corresponds With Activity of JNK, the c-jun N-Terminal Kinase , 1998 .

[148]  C. Eaves,et al.  Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. , 1997, Blood.

[149]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[150]  J. Dick,et al.  Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. , 1996, Blood.

[151]  M. Andreeff,et al.  Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. , 1995, Blood.

[152]  J. Radich,et al.  Benign marrow progenitors are enriched in the CD34+/HLA-DRlo population but not in the CD34+/CD38lo population in chronic myeloid leukemia: an analysis using interphase fluorescence in situ hybridization. , 1995, Blood.

[153]  M. Karin,et al.  JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers. , 1993, Genes & development.

[154]  A. Eaves,et al.  Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[155]  O. Witte,et al.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.

[156]  J. Stephenson,et al.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 , 1984, Cell.

[157]  J. Stephenson,et al.  Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia , 1983, Nature.

[158]  Shaoguang Li,et al.  β-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia , 2009, Leukemia.

[159]  H. Klamová,et al.  WT1 expression in peripheral leukocytes of patients with chronic myeloid leukemia serves for the prediction of Imatinib resistance. , 2009, Neoplasma.

[160]  R M Stone,et al.  Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib , 2008, Leukemia.

[161]  J. Cayuela,et al.  Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. , 2007, Blood.

[162]  C. Bokemeyer,et al.  Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. , 2006, Cancer research.

[163]  T. Holyoake,et al.  Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.

[164]  J. Goldman,et al.  Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission , 2000 .

[165]  C. Verfaillie,et al.  BCR/ABL- CD34+HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal , 1999 .